Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 38, Issue 9

Issues

P-Glycoprotein and Bioavailability-Implication of Polymorphism

Yan Liu / Ming Hu
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2000.127

Abstract

P-Glycoprotein (P-gp) may have a significant impact on systemic and tissue/cellular bioavailability of drugs because it functions as an “anti-absorption” mechanism that effluxes drug molecules out of the lipid bilayer and cytoplasm. The ability to reduce bioavailability at the tissue/cellular level was first discovered during the investigation of the causes of multidrug resistance (MDR) in cancer chemotherapy. Initially, it was thought that MDR is only caused by P-gp. Recently, many other transporters such as multidrug resistance-related protein (MRP) have also been identified. The ability of P-gp to impact systemic drug bioavailability was only recently recognized. Dr. Alfred Schinkel's group was first to show a significant improvement in the systemic bioavailability of several drugs in the MDR1 knockout mice. The same group also discovered that the blood-brain barrier (BBB) has a very high expression level of P-gp, and that this protein is necessary to restrict the entrance of various drug molecules into the central nervous system (CNS).

Polymorphism in the normal human cells has not been reported, but it has been discovered in human cancer cells. Functional implication of P-gp polymorphism in changing the tissue bioavailability has been studied in rodents. These studies strongly support the role of P-gp in restricting tissue bioavailability of anticancer drugs. These studies also support the effectiveness of P-gp in limiting CNS toxicity of the cytotoxic drugs.

The functional implication of P-gp on systemic bioavailability is much less well defined in humans, although it appears to be quite obvious in MDR1 knockout mice. Pharmacokinetic models clearly suggest that a change in the absorption rate will have a significant impact on systemic blood level of a drug. However, whether functionally significant polymorphisms of P-gp exist in humans has not been determined. If they do exist, they will surely impact on both systemic bioavailability and drug interaction potentials of many drugs.

In the drug development process, several models may be used to select a lead compound that may or may not interact with P-gp, depending on whether the interaction is desirable. Several inhibitors of P-gp are currently on the clinical trial stage. Natural inhibitors of P-gp have also been discovered. There is no doubt that these new developments will have significant impact on the bioavailability of a variety of anticancer and CNS drugs in the next decades.

About the article

Published Online: 2005-06-01

Published in Print: 2000-09-18


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 38, Issue 9, Pages 877–881, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2000.127.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Chava Kimchi-Sarfaty, John J. Gribar, and Michael M. Gottesman
Molecular Pharmacology, 2002, Volume 62, Number 1, Page 1
[2]
Soichi Haraguchi, Sarah K. Ho, Matthew Morrow, Maureen M. Goodenow, and John W. Sleasman
Journal of Leukocyte Biology, 2011, Volume 90, Number 4, Page 653
[3]
Robert A. Johnson, Erica M. Shepard, and Kathleen W. Scotto
Journal of Biological Chemistry, 2005, Volume 280, Number 14, Page 13213
[4]
Zoulikha M Zaïr and Donald RJ Singer
Pharmacogenomics, 2016, Volume 17, Number 9, Page 1089
[5]
J Dupouy-Camet, H Yera, and C Tourte-Schaefer
Archives de Pédiatrie, 2003, Volume 10, Page s545
[6]
Silvio Garattini
European Journal of Cancer, 2007, Volume 43, Number 2, Page 271
[7]
Katrina L. Mealey, Steven A. Bentjen, and Denise K. Waiting
American Journal of Veterinary Research, 2002, Volume 63, Number 4, Page 479
[8]
C. Hugnet, S. A. Bentjen, and K. L. Mealey
Journal of Veterinary Pharmacology and Therapeutics, 2004, Volume 27, Number 4, Page 227

Comments (0)

Please log in or register to comment.
Log in